Market Cap 814.31M
Revenue (ttm) 403.14M
Net Income (ttm) -22.68M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -5.63%
Debt to Equity Ratio -0.50
Volume 7,879,300
Avg Vol 14,292,372
Day's Range N/A - N/A
Shares Out 257.69M
Stochastic %K 75%
Beta 1.07
Analysts Hold
Price Target $2.97

Company Profile

Esperion Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company's marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia cardiovascular disease who...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 734 887 3903
Address:
3891 Ranchero Drive, Suite 150, Ann Arbor, United States
Enjoyycall
Enjoyycall Jul. 4 at 9:03 PM
$ESPR 🇺🇸
0 · Reply
Enjoyycall
Enjoyycall Jul. 4 at 4:04 PM
$ESPR 🤠🇺🇸🫡🫡🫡🫡🫡🫡
0 · Reply
Gregg617
Gregg617 Jul. 4 at 3:53 PM
$ESPR pro tip if you’re setting up fireworks today make sure your wheelchair is charged. #Terry
0 · Reply
Rustyton
Rustyton Jul. 3 at 5:06 PM
$ESPR scripts ?
1 · Reply
BBRC
BBRC Jul. 3 at 3:51 AM
$ESPR Based on the ISS normal publishing schedule it appears as it they never bothered to review this deal. Still expecting Glass Lewis to review it and publish a recommendation. They typically publish closer to the vote. If Glass Lewis recommends against this deal that will create a situation where the vote could fail. This could produce a topping bid or Archimed bumps the buyout price to try and secure the vote.
2 · Reply
Gregg617
Gregg617 Jul. 2 at 11:11 PM
$ESPR Happy 4th
1 · Reply
josh23941
josh23941 Jul. 2 at 8:37 PM
0 · Reply
josh23941
josh23941 Jul. 2 at 7:56 PM
0 · Reply
biotech_sellout
biotech_sellout Jul. 2 at 6:36 PM
$ESPR A stroll down memory lane
0 · Reply
Enjoyycall
Enjoyycall Jul. 2 at 6:21 PM
$ESPR Soon!
2 · Reply
Latest News on ESPR
Esperion Therapeutics Proxy statement: Proxy filing

Jun 16, 2026, 8:00 AM EDT - 18 days ago

Esperion Therapeutics Proxy statement: Proxy filing


Esperion Therapeutics Proxy statement: Proxy filing

Jun 8, 2026, 8:00 AM EDT - 26 days ago

Esperion Therapeutics Proxy statement: Proxy filing


Esperion Therapeutics Proxy statement: Proxy filing

May 29, 2026, 8:00 AM EDT - 5 weeks ago

Esperion Therapeutics Proxy statement: Proxy filing


Esperion Therapeutics Transcript: AGM 2026

May 28, 2026, 8:00 AM EDT - 5 weeks ago

Esperion Therapeutics Transcript: AGM 2026


Esperion Therapeutics Quarterly report: Q1 2026

May 8, 2026, 7:00 AM EDT - 2 months ago

Esperion Therapeutics Quarterly report: Q1 2026


Esperion downgraded to Hold from Buy at Needham

2026-05-04T19:10:14.000Z - 2 months ago

Esperion downgraded to Hold from Buy at Needham


Esperion Therapeutics Proxy statement: Proxy filing

May 4, 2026, 8:00 AM EDT - 2 months ago

Esperion Therapeutics Proxy statement: Proxy filing


Esperion downgraded to Hold from Buy at Jefferies

2026-05-01T19:26:03.000Z - 2 months ago

Esperion downgraded to Hold from Buy at Jefferies


Esperion downgraded to Neutral from Overweight at Piper Sandler

2026-05-01T18:06:50.000Z - 2 months ago

Esperion downgraded to Neutral from Overweight at Piper Sandler


Esperion downgraded to Neutral from Buy at H.C. Wainwright

2026-05-01T15:12:52.000Z - 2 months ago

Esperion downgraded to Neutral from Buy at H.C. Wainwright


Esperion Therapeutics Proxy statement: Proxy filing

May 1, 2026, 8:00 AM EDT - 2 months ago

Esperion Therapeutics Proxy statement: Proxy filing


Esperion Therapeutics Proxy statement: Proxy filing

May 1, 2026, 8:00 AM EDT - 2 months ago

Esperion Therapeutics Proxy statement: Proxy filing


Esperion to be Acquired by ARCHIMED

May 1, 2026, 7:00 AM EDT - 2 months ago

Esperion to be Acquired by ARCHIMED


Esperion to Report First Quarter 2026 Financial Results on May 7

Apr 23, 2026, 8:00 AM EDT - 2 months ago

Esperion to Report First Quarter 2026 Financial Results on May 7


Esperion Therapeutics Proxy statement: Proxy filing

Apr 16, 2026, 8:00 AM EDT - 2 months ago

Esperion Therapeutics Proxy statement: Proxy filing


Esperion Therapeutics Proxy statement: Proxy filing

Apr 16, 2026, 8:00 AM EDT - 2 months ago

Esperion Therapeutics Proxy statement: Proxy filing


Esperion showcases new data from CLEAR Outcomes trial

2026-03-30T13:21:46.000Z - 3 months ago

Esperion showcases new data from CLEAR Outcomes trial


Esperion price target raised to $5 from $4 at Citizens

2026-03-13T09:36:20.000Z - 4 months ago

Esperion price target raised to $5 from $4 at Citizens


Esperion Therapeutics Earnings Call Transcript: Q4 2025

Mar 10, 2026, 8:00 AM EDT - 4 months ago

Esperion Therapeutics Earnings Call Transcript: Q4 2025


Esperion Therapeutics Annual report: Q4 2025

Mar 10, 2026, 8:00 AM EDT - 4 months ago

Esperion Therapeutics Annual report: Q4 2025


Esperion Therapeutics Earnings release: Q4 2025

Mar 10, 2026, 8:00 AM EDT - 4 months ago

Esperion Therapeutics Earnings release: Q4 2025


Esperion Therapeutics Slides: Q4 2025

Mar 10, 2026, 8:00 AM EDT - 4 months ago

Esperion Therapeutics Slides: Q4 2025


Esperion reports Q4 EPS 22c, consensus 28c

2026-03-10T10:06:52.000Z - 4 months ago

Esperion reports Q4 EPS 22c, consensus 28c


Esperion Therapeutics Slides: Corporate presentation

Mar 9, 2026, 7:00 AM EDT - 4 months ago

Esperion Therapeutics Slides: Corporate presentation


Esperion Therapeutics Transcript: M&A announcement

Mar 3, 2026, 8:00 AM EST - 4 months ago

Esperion Therapeutics Transcript: M&A announcement


Esperion Therapeutics Press release: M&A announcement

Mar 3, 2026, 8:00 AM EST - 4 months ago

Esperion Therapeutics Press release: M&A announcement


Esperion Therapeutics Slides: M&A announcement

Mar 3, 2026, 8:00 AM EST - 4 months ago

Esperion Therapeutics Slides: M&A announcement


Esperion signs definitive acquisition of Corstasis Therapeutics

2026-03-03T11:05:38.000Z - 4 months ago

Esperion signs definitive acquisition of Corstasis Therapeutics


Esperion reaches settlement agreement with Alkem

2026-02-17T13:16:28.000Z - 4 months ago

Esperion reaches settlement agreement with Alkem


Esperion Therapeutics Transcript: KOL Event

Nov 11, 2025, 2:00 PM EST - 8 months ago

Esperion Therapeutics Transcript: KOL Event


Esperion Therapeutics Slides: KOL Event

Nov 11, 2025, 2:00 PM EST - 8 months ago

Esperion Therapeutics Slides: KOL Event


Esperion Therapeutics Earnings Call Transcript: Q3 2025

Nov 6, 2025, 8:00 AM EST - 8 months ago

Esperion Therapeutics Earnings Call Transcript: Q3 2025


Esperion Therapeutics Quarterly report: Q3 2025

Nov 6, 2025, 8:00 AM EST - 8 months ago

Esperion Therapeutics Quarterly report: Q3 2025


Esperion Therapeutics Earnings release: Q3 2025

Nov 6, 2025, 8:00 AM EST - 8 months ago

Esperion Therapeutics Earnings release: Q3 2025


Esperion Therapeutics Slides: Q3 2025

Nov 6, 2025, 8:00 AM EST - 8 months ago

Esperion Therapeutics Slides: Q3 2025


Esperion Announces Pricing of Public Offering of Common Stock

Oct 7, 2025, 9:29 PM EDT - 9 months ago

Esperion Announces Pricing of Public Offering of Common Stock


Esperion Announces Proposed Public Offering of Common Stock

Oct 7, 2025, 4:01 PM EDT - 9 months ago

Esperion Announces Proposed Public Offering of Common Stock


Esperion Therapeutics Earnings Call Transcript: Q2 2025

Aug 5, 2025, 8:00 AM EDT - 11 months ago

Esperion Therapeutics Earnings Call Transcript: Q2 2025


Esperion Therapeutics Quarterly report: Q2 2025

Aug 5, 2025, 8:00 AM EDT - 11 months ago

Esperion Therapeutics Quarterly report: Q2 2025


Esperion Therapeutics Earnings release: Q2 2025

Aug 5, 2025, 8:00 AM EDT - 11 months ago

Esperion Therapeutics Earnings release: Q2 2025


Esperion Therapeutics Slides: Q2 2025

Aug 5, 2025, 8:00 AM EDT - 11 months ago

Esperion Therapeutics Slides: Q2 2025


Esperion Appoints Craig Thompson to Board of Directors

Jul 1, 2025, 8:06 AM EDT - 1 year ago

Esperion Appoints Craig Thompson to Board of Directors


Esperion Therapeutics Earnings Call Transcript: Q1 2025

May 6, 2025, 8:00 AM EDT - 1 year ago

Esperion Therapeutics Earnings Call Transcript: Q1 2025


Esperion Therapeutics Quarterly report: Q1 2025

May 6, 2025, 8:00 AM EDT - 1 year ago

Esperion Therapeutics Quarterly report: Q1 2025


Esperion Therapeutics Earnings release: Q1 2025

May 6, 2025, 8:00 AM EDT - 1 year ago

Esperion Therapeutics Earnings release: Q1 2025


Esperion Therapeutics Slides: Q1 2025

May 6, 2025, 8:00 AM EDT - 1 year ago

Esperion Therapeutics Slides: Q1 2025


Esperion Therapeutics Transcript: Status Update

Apr 24, 2025, 9:00 AM EDT - 1 year ago

Esperion Therapeutics Transcript: Status Update


Esperion Therapeutics Press release: Status Update

Apr 24, 2025, 9:00 AM EDT - 1 year ago

Esperion Therapeutics Press release: Status Update


Esperion Therapeutics Slides: Status Update

Apr 24, 2025, 9:00 AM EDT - 1 year ago

Esperion Therapeutics Slides: Status Update


Esperion Therapeutics Proxy statement: Proxy Filing

Apr 17, 2025, 8:00 AM EDT - 1 year ago

Esperion Therapeutics Proxy statement: Proxy Filing


Esperion Therapeutics Proxy statement: Proxy Filing

Apr 17, 2025, 8:00 AM EDT - 1 year ago

Esperion Therapeutics Proxy statement: Proxy Filing


Esperion Appoints Robert E. Hoffman to Board of Directors

Apr 1, 2025, 8:00 AM EDT - 1 year ago

Esperion Appoints Robert E. Hoffman to Board of Directors


Esperion Therapeutics Earnings Call Transcript: Q4 2024

Mar 4, 2025, 8:00 AM EST - 1 year ago

Esperion Therapeutics Earnings Call Transcript: Q4 2024


Esperion Therapeutics Annual report: Q4 2024

Mar 4, 2025, 8:00 AM EST - 1 year ago

Esperion Therapeutics Annual report: Q4 2024


Esperion Therapeutics Earnings release: Q4 2024

Mar 4, 2025, 8:00 AM EST - 1 year ago

Esperion Therapeutics Earnings release: Q4 2024


Esperion Therapeutics Slides: Q4 2024

Mar 4, 2025, 8:00 AM EST - 1 year ago

Esperion Therapeutics Slides: Q4 2024


Esperion Therapeutics Transcript: KOL Event

Jan 22, 2025, 12:30 PM EST - 1 year ago

Esperion Therapeutics Transcript: KOL Event


Esperion Therapeutics Slides: KOL Event

Jan 22, 2025, 12:30 PM EST - 1 year ago

Esperion Therapeutics Slides: KOL Event


Esperion Therapeutics Slides: FY 2025

Jan 15, 2025, 6:45 PM EST - 1 year ago

Esperion Therapeutics Slides: FY 2025


Esperion Announces $210 Million Convertible Debt Financing

Dec 13, 2024, 6:00 AM EST - 1 year ago

Esperion Announces $210 Million Convertible Debt Financing


Esperion Therapeutics Earnings Call Transcript: Q3 2024

Nov 7, 2024, 8:00 AM EST - 1 year ago

Esperion Therapeutics Earnings Call Transcript: Q3 2024


Esperion Therapeutics Quarterly report: Q3 2024

Nov 7, 2024, 8:00 AM EST - 1 year ago

Esperion Therapeutics Quarterly report: Q3 2024


Esperion Therapeutics Earnings release: Q3 2024

Nov 7, 2024, 8:00 AM EST - 1 year ago

Esperion Therapeutics Earnings release: Q3 2024


Esperion Therapeutics Slides: Q3 2024

Nov 7, 2024, 8:00 AM EST - 1 year ago

Esperion Therapeutics Slides: Q3 2024


Esperion Therapeutics Earnings Call Transcript: Q2 2024

Aug 12, 2024, 8:00 AM EDT - 2 years ago

Esperion Therapeutics Earnings Call Transcript: Q2 2024


Esperion Therapeutics Quarterly report: Q2 2024

Aug 12, 2024, 8:00 AM EDT - 2 years ago

Esperion Therapeutics Quarterly report: Q2 2024


Esperion Therapeutics Earnings release: Q2 2024

Aug 12, 2024, 8:00 AM EDT - 2 years ago

Esperion Therapeutics Earnings release: Q2 2024


Esperion Therapeutics Slides: Q2 2024

Aug 12, 2024, 8:00 AM EDT - 2 years ago

Esperion Therapeutics Slides: Q2 2024


Esperion Therapeutics Slides: Corporate Presentation

Aug 8, 2024, 7:00 AM EDT - 2 years ago

Esperion Therapeutics Slides: Corporate Presentation


Enjoyycall
Enjoyycall Jul. 4 at 9:03 PM
$ESPR 🇺🇸
0 · Reply
Enjoyycall
Enjoyycall Jul. 4 at 4:04 PM
$ESPR 🤠🇺🇸🫡🫡🫡🫡🫡🫡
0 · Reply
Gregg617
Gregg617 Jul. 4 at 3:53 PM
$ESPR pro tip if you’re setting up fireworks today make sure your wheelchair is charged. #Terry
0 · Reply
Rustyton
Rustyton Jul. 3 at 5:06 PM
$ESPR scripts ?
1 · Reply
BBRC
BBRC Jul. 3 at 3:51 AM
$ESPR Based on the ISS normal publishing schedule it appears as it they never bothered to review this deal. Still expecting Glass Lewis to review it and publish a recommendation. They typically publish closer to the vote. If Glass Lewis recommends against this deal that will create a situation where the vote could fail. This could produce a topping bid or Archimed bumps the buyout price to try and secure the vote.
2 · Reply
Gregg617
Gregg617 Jul. 2 at 11:11 PM
$ESPR Happy 4th
1 · Reply
josh23941
josh23941 Jul. 2 at 8:37 PM
0 · Reply
josh23941
josh23941 Jul. 2 at 7:56 PM
0 · Reply
biotech_sellout
biotech_sellout Jul. 2 at 6:36 PM
$ESPR A stroll down memory lane
0 · Reply
Enjoyycall
Enjoyycall Jul. 2 at 6:21 PM
$ESPR Soon!
2 · Reply
BullDonald
BullDonald Jul. 2 at 5:04 PM
$ESPR Happy 4th July, glad you got 1 cent bull move before the vacation.😏
0 · Reply
Rustyton
Rustyton Jul. 2 at 4:24 PM
$ESPR Sheldon screwed long term holders. Asked for patience and promised long term results only to pull the rug after diluting them to smithereens. I really hope karma gets him
3 · Reply
Gary9912
Gary9912 Jul. 2 at 12:03 PM
$ESPR As judgement day approaches, rest assured that I’ll be back, either to collect more cash from a competing bid or with a lawyer!💰
0 · Reply
profitsforall
profitsforall Jul. 2 at 11:46 AM
$ESPR Oops, forgot to add the "Conspiracy to commit Mail fraud, Wire Fraud, Criminal Securities Fraud violations, etc..." Money Laundering? Lots to choose from... 5 years statute of limitations....this may not end when a deal closes, it may be just the beginning..
0 · Reply
BingusCat
BingusCat Jul. 2 at 1:14 AM
$AKBA $ESPR telling you team, take a high level look. Real company real products.
1 · Reply
Gary9912
Gary9912 Jul. 1 at 11:58 PM
$ESPR A close shot up of the banner held by the two protesters that climbed the Empire State Building today is pictured below. Side note, @Gregg617 was ironically in NY today on business and he was not answering calls and texts…hmmm🤷‍♂️😂
1 · Reply
BBRC
BBRC Jul. 1 at 9:21 PM
$ESPR All eyes are now on Glass Lewis.
2 · Reply
BBRC
BBRC Jul. 1 at 9:20 PM
$ESPR It appears that ISS could not be bothered to review this deal. That is unfortunate.
1 · Reply
Gary9912
Gary9912 Jul. 1 at 2:18 PM
$ESPR $3.16 /$3.17
0 · Reply
profitsforall
profitsforall Jun. 30 at 10:54 PM
$ESPR PS: On most potential criminal charges it is a 5 year statute of limitations.
0 · Reply
Gary9912
Gary9912 Jun. 30 at 10:18 PM
$ESPR Nothibg really ever made sense here so would would the BO make sense. ( too low and trading above BO price quite town, which is very rare!!!) the good thing is whatever will or won’t happen here, we should all be getting set free pretty soon!
3 · Reply
Huso123456
Huso123456 Jun. 30 at 8:24 PM
$ESPR It's a good thing I sold here and moved to SLS. Even if another offer comes along here—which I hope it does for everyone who stuck it out here—it won't come close to the profit I've made at SLS over the last few days. And things are just getting started there. I think prices above $20 shouldn't be too far off.
1 · Reply